diology, targeting the rare population impacted by these conditions,” said David Weinreich, MD, Head of Research and Development and Chief Medical Officer, Healthcare business of Merck. “By leveraging Saturnus' expertise and cutting-edge approach, we can build upon our armed antibodies capabilities and explore novel directions to rapidly bring new, targeted treatments to patients.”

“The launch of Saturnus through a foundational partnership with Merck exemplifies Versant’s strategy of engaging with pharma to develop a new frontier of medicines in areas of important unmet medical need,” said Rick Dewey, MD, an entrepreneur-in-residence at Versant Ventures and CEO of Saturnus. “The company is in strong position to accelerate development of its pipeline of first-in-class medicines for genetic cardiomyopathies.”

The research-stage partnership entails a build-to-buy deal structure, including an upfront payment of ￥50 mil
=*=*=*=*=*=
当前为第2/5页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页